RY3
SUSMi001-A
General
Cell Line |
|
hPSCreg Name | SUSMi001-A |
Alternative name(s) |
RY3
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | |
Last update | 22nd May 2019 |
User feedback | |
Provider |
|
Generator | Stanford University School of Medicine (SUSM) |
External Databases |
|
BioSamples | SAMEA4909539 |
Cellosaurus | CVCL_UM29 |
CLO | CLO_0102295 |
Wikidata | Q98132883 |
General Information |
|
Projects | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Subclones |
Donor Information
General Donor Information |
|
Sex | male |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
Donor Relations |
|
Other cell lines of this donor | |
External Databases (Donor) |
|
BioSamples | SAMEA4909540 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
Provide contact information of the holder of the original Donor Information Sheet: | |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Contact information / weblink | Mary Ulman, mary.ulman@ucsf.edu |
Alternatives to consent | |
Alternative consent approval number | |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Details on restriction to research project | |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Open Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Please describe how access is provided: | |
Contact data, institution, or website: | |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | University of California San Francisco Institutional Review Board |
Approval number | 13-10806 |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | University of California San Francisco Institutional Review Board |
Approval number | 13-10806 |
Please describe: | |
Further constraints on use | |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
Constraints for use or distribution |
hIPSC Derivation
General |
|
Source cell type |
fibroblastA connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.
|
Source cell origin |
skin of backA zone of skin that is part of a back [Automatically generated definition].
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Episomal |
Is reprogramming vector detectable? |
Yes |
Notes on reprogramming vector detection | Southern Blot |
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Medium |
Other medium:
Base medium: Knockout DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
NANOG |
Yes |
|
||||
TRA 1-81 |
Yes |
|
||||
POU5F1 (OCT-4) |
Yes |
|
||||
TRA 1-60 |
Yes |
|
Score:
Marker | Present | Absent |
mCpG | ||
OCT4 |
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
normal
Passage number: 20
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.